CD274 and neoplasm: We further analyzed the blood tumor variation burden status of 5 patients with PFS of at least 3 months who had PD-L1 TPS of less than 1%; 4 (80.0%) had sufficient blood samples, and the median blood tumor variation burden was 12.5 mutations per megabase pairs.